A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD Study
Phase of Trial: Phase III
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms REBUILD
- Sponsors Eli Lilly
- 12 Mar 2018 Planned number of patients changed from 274 to 224.
- 12 Mar 2018 Status changed from not yet recruiting to recruiting.
- 15 Feb 2018 New trial record